Barclays raised the firm’s price target on Elevance Health (ELV) to $512 from $501 and keeps an Overweight rating on the shares post the Q4 ...

Elevance Health Inc. closed $174.10 below its 52-week high ($567.26), which the company achieved on September 3rd.

Stocks closed solidly higher on Thursday for the fourth straight session as investor optimism about the Trump administration continues to run high.

Elevance Health (ELV – Research Report) received a Buy rating and a $485.00 price target from Cantor Fitzgerald analyst Sarah James yesterday.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Elevance Health jumped early Thursday in response to better-than-expected fourth- quarter results, and a generally optimistic outlook for the coming year. A week after UnitedHealth Group ...

UnitedHealth beat fourth-quarter earnings forecast, though revenue fell short and medical costs ran high, hitting the Dow Jones component.

Shares of Elevance Health Inc. ELV slumped 0.69 ... with the S&P 500 Index SPX falling 1.11% to 5,970.84 and Dow Jones Industrial Average DJIA falling 0.77% to 42,992.21. The stock's fall snapped ...

Sources: FactSet, Dow Jones Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet ...